Tag - ZSAN

Markets

BTIG cuts Zosano to neutral from buy; removes PT

BTIG downgraded Zosano Pharma (NASDAQ:ZSAN) to “neutral” from “buy” and removed its price target after the FDA refused to accept the company’s NDA resubmission for M207 to treat acute migraine. Shares of Zosano, which...

February 23, 2022

Markets

BTIG cuts Zosano Pharma PT to $2 from $7

BTIG slashed the price target for Zosano Pharma (NASDAQ:ZSAN) to $2 from $7, citing a complete response letter about the NDA for Qtrypta, a transdermal microneedle system form of zolmitriptan in development for acute...

October 22, 2020

Developments

Zosano Pharma begins enrollment in Phase 2/3 cluster headache trial

Zosano Pharma (NASDAQ:ZSAN) has begun enrolling cluster headache patients in its Phase 2/3 study evaluating C213 for the acute treatment of cluster headache. C213 consists of the same formulation of zolmitriptan as the...

October 24, 2019

Tag - ZSAN

BTIG cuts Zosano to neutral from buy; removes PT

BTIG cuts Zosano Pharma PT to $2 from $7

Zosano Pharma begins enrollment in Phase 2/3 cluster headache trial

General

More